摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(E)-7-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)hept-1-ene-1,3-diol

中文名称
——
中文别名
——
英文名称
(E)-7-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)hept-1-ene-1,3-diol
英文别名
——
(E)-7-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)hept-1-ene-1,3-diol化学式
CAS
——
化学式
C15H22N2O2
mdl
——
分子量
262.35
InChiKey
KEFSKYDPJBDEKO-PKNBQFBNSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.2
  • 重原子数:
    19
  • 可旋转键数:
    6
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.53
  • 拓扑面积:
    65.4
  • 氢给体数:
    3
  • 氢受体数:
    4

文献信息

  • FLUORINATED INTEGRIN ANTAGONISTS
    申请人:Scifluor Life Sciences, Inc
    公开号:EP2953948B1
    公开(公告)日:2017-09-27
  • US9717729B2
    申请人:——
    公开号:US9717729B2
    公开(公告)日:2017-08-01
  • [EN] FLUORINATED INTEGRIN ANTAGONISTS<br/>[FR] ANTAGONISTES DE L'INTÉGRINE FLUORÉS
    申请人:SCIFLUOR LIFE SCIENCES LLC
    公开号:WO2014124302A1
    公开(公告)日:2014-08-14
    The present invention relates to fluorinated compounds of formula I and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing the fluorinated compounds of the invention, and methods of treating macular degeneration, diabetic retinopathy (DR), macular edema, diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), by administering these compounds and pharmaceutical compositions to subjects in need thereof.
  • [EN] FLUORINATED TETRAHYDRONAPHTHYRIDINYL NONANOIC ACID DERIVATIVES AND USES THEREOF<br/>[FR] DÉRIVÉS D'ACIDE NONANOÏQUE TÉTRAHYDRONAPHTHYRIDINYLE FLUORÉS ET LEURS UTILISATIONS
    申请人:SCIFLUOR LIFE SCIENCES INC
    公开号:WO2016134223A2
    公开(公告)日:2016-08-25
    The present invention relates to fluorinated compounds of formula I and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing the fluorinated compounds of the invention, and methods of treating fibrosis, macular degeneration, diabetic retinopathy (DR), macular edema, diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), by administering these compounds and pharmaceutical compositions to subjects in need thereof.
查看更多